Cullinan Therapeutics Files Q1 2025 10-Q
Ticker: CGEM · Form: 10-Q · Filed: May 8, 2025 · CIK: 1789972
| Field | Detail |
|---|---|
| Company | Cullinan Therapeutics, Inc. (CGEM) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, financials, sec-filing
Related Tickers: CGEM
TL;DR
Cullinan Therapeutics (CGEM) filed its Q1 2025 10-Q. Financials updated.
AI Summary
Cullinan Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Cullinan Oncology, Inc., is involved in biological products. Key financial data and fair value measurements for various securities, including corporate notes and US government debt, are detailed in the filing.
Why It Matters
This filing provides investors with an update on Cullinan Therapeutics' financial position and operational details for the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a biotechnology company, Cullinan Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End (This is the end date for the financial reporting period covered by the 10-Q.)
- 2025-05-08 — Filing Date (This is the date the 10-Q was officially filed with the SEC.)
- 2024-12-31 — Previous Year End (Indicates financial data points from the end of the prior fiscal year.)
Key Players & Entities
- Cullinan Therapeutics, Inc. (company) — Filer of the 10-Q
- Cullinan Oncology, Inc. (company) — Former name of the filer
- 20250331 (date) — Reporting period end date
- 20250508 (date) — Filing date
- 001-39856 (dollar_amount) — SEC file number
FAQ
What is the primary business of Cullinan Therapeutics, Inc.?
Cullinan Therapeutics, Inc. is involved in the business of Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code [2836].
When was Cullinan Therapeutics, Inc. previously known by another name?
The company was formerly known as Cullinan Oncology, Inc., with a name change effective February 25, 2021.
What is the SEC file number for Cullinan Therapeutics, Inc.?
The SEC file number for Cullinan Therapeutics, Inc. is 001-39856.
What is the fiscal year end for Cullinan Therapeutics, Inc.?
The fiscal year end for Cullinan Therapeutics, Inc. is December 31 (1231).
What types of investments are mentioned in relation to fair value measurements for the period ending March 31, 2025?
The filing mentions fair value measurements for us-gaap:CorporateNoteSecuritiesMember and us-gaap:FairValueInputsLevel3Member for the period ending March 31, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Cullinan Therapeutics, Inc. (CGEM).